Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 9/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL342718 | 1.00 | RORC (0.37) | RORCNR1H2EPHX2GPR119USP2 | |
| SCHEMBL28708135 | 0.81 | RORC (0.41) | RORCNR1H2EPHX2USP2SMN1; SMN2 | |
| SCHEMBL321486 | 0.79 | NR1H2 (0.47) | NR1H2GPR119USP2SMN1; SMN2 | |
| SCHEMBL2217516 | 0.78 | RORC (0.40) | RORCNR1H2EPHX2USP2SMN1; SMN2 | |
| SCHEMBL18210065 | 0.78 | RORC (0.40) | RORCNR1H2EPHX2USP2SMN1; SMN2 | |
| SCHEMBL1268620 | 0.77 | NR1H2 (0.33) | NR1H2EPHX2GPR119 | |
| SCHEMBL16233283 | 0.77 | JAK1 (0.43) | RORCNR1H2EPHX2GPR119USP2 | |
| SCHEMBL16199575 | 0.77 | JAK1 (0.43) | RORCNR1H2EPHX2GPR119USP2 | |
| SCHEMBL14661920 | 0.76 | EPHX2 (0.38) | NR1H2EPHX2GPR119USP2SMN1; SMN2 | |
| SCHEMBL24070869 | 0.75 | CHRM2 (0.35) | NR1H2EPHX2GPR119USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367690-B2 | Aminopyridine derivatives having aurora a selective inhibitory action | VERTEX PHARMACEUTICALS INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120015969-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICALS CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015969-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | AURKA, AURKC, AURKB | RORC 3867/4885NR1H2 3181/4885EPHX2 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.